Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Duration: October 1, 2008
to
April 15, 2013
General Issues: Health Issues , Medical/Disease Research/Clinical Labs , Pharmacy , Law Enforcement/Crime/Criminal Justice
Spending: about $201,508 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Dennis DeConcini U.S. Senator, 1977 to 1995
James Rock Staff Asst, US House Committee on Budget - 1985 to 2000
Thaddeus Strom Chief Counsel, Sen Strom Thurmond - 1987 to 1988
Gen Counsel/Staff Dir, Sen Cmte on the Judiciary - 1988-1991
Chief Counsel/Staff Dir, Sen Cmte on the Judiciary-1991-1993
Chief Counsel/Staff Dir, Sen Subcommittee on Antitrust,
Business Rights and Competition - 1994-1997
Steve Symms U.S. Senator, 1981 to 1993
Edward Baxter Chief Counsel and Staff Director, Senate Judiciary
Committee's Subcomm. on Patents, Copyrights,
and Trademarks: 1987 to 1990
Romano Romani n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2013
PARRY, ROMANI, DECONCINI & SYMMS terminated an engagement in which they represented Wedgewood Village Pharmacy, Inc. on May 20, 2013.
Original Filing: 300567599.xml
Lobbying Issues
Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2013
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on April 16, 2013.
Original Filing: 300550930.xml
Lobbying Issues
Issues related to the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2012
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on Jan. 11, 2013.
Original Filing: 300527730.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
H.R. 6584, Verifying Authority and Legality In Drug Compounding Act of 2012.
H.R. 6638, S.A.F.E. Compounded Drugs Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Regulatory issues involving compounded 17P and compounded Avastin.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2012
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on Oct. 5, 2012.
Original Filing: 300504144.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Regulatory issues involving compounded 17P and compounded Avastin.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2012
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on July 12, 2012.
Original Filing: 300483144.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Regulatory issues involving compounded 17P and compounded Avastin.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2012
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on April 11, 2012.
Original Filing: 300459138.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Regulatory issues involving compounded 17P and compounded Avastin.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2011
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on Jan. 19, 2012.
Original Filing: 300445309.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Regulatory issues involving compounded 17P and compounded Avastin.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on Oct. 17, 2011.
Original Filing: 300415608.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on July 8, 2011.
Original Filing: 300387115.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
Proposals to amend the Controlled Substances Act to clarify the definition of "dispense" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice. No specific legislation yet.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,508. The report was filed on April 11, 2011.
Original Filing: 300361898.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on Jan. 14, 2011.
Original Filing: 300338852.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on Oct. 12, 2010.
Original Filing: 300310622.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet.
H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on July 15, 2010.
Original Filing: 300287767.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
H.R. 3018, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on April 7, 2010.
Original Filing: 300254991.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
H.R. 3018, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on Jan. 13, 2010.
Original Filing: 300230263.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
H.R. 3018, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on Oct. 8, 2009.
Original Filing: 300202032.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on July 17, 2009.
Original Filing: 300182820.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $11,250. The report was filed on April 17, 2009.
Original Filing: 300153045.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet.Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Wedgewood Village Pharmacy, Inc. , earning $10,000. The report was filed on Jan. 15, 2009.
Original Filing: 300120255.xml
Lobbying Issues
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page).Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and
Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Disease Research/Clinical Labs
4th Quarter, 2008
PARRY, ROMANI, DECONCINI & SYMMS filed a lobbying registration on Nov. 23, 2008 to represent Wedgewood Village Pharmacy, Inc., effective Oct. 1, 2008.
Original Filing: 300111981.xml
Issue(s) they said they’d lobby about: Issues related to compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drig Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate). .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...